Side population rather than CD133+ cells distinguishes enriched tumorigenicity in hTERT-immortalized primary prostate cancer cells

Table 1 Tumorigenicity of CD133+ or CD133- Fractions in hTERT immortalized cell lines.

For hTERT-immortalized human primary prostate cancer cell line RC-58T/hTERT/SA#4-D, NOD/SCID mice were killed at 16 weeks post-injection. For RC-92a/hTERT, mice were killed at 23 weeks post-injection since RC-92a/hTERT xenograft tumor grows very slowly. For SCID5083-6, mice were killed at 16-17 weeks post-injection. For RC-193a/hTERT, mice were killed at 15-23 weeks post-injection. For SCID5080A-1, mice were sacrificed at 15-23 weeks post-injection. Mice were considered positive if palpable tumor tissue was identified. All the doses except that only resulted in negative mice were used to calculate the limiting dilution experiments. Confidence interval was displayed in the bracket. SCID5083-6 and SCID5080A-1 xenograft tumors grows faster than its parental RC-92a/hTERT, RC-193a/hTERT xenograft tumors, respectively.

ISSN: 1476-4598